Extracellular matrix component signaling in cancer

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 28-40

  Multhaupt, Hinke A B ^a,b   Leitinger, Birgit ^c   Gullberg, Donald ^d   Couchman, John R ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Adhesion; Discoidin domain receptors; Integrin; Migration; Proteoglycan; Syndecan

Indexed keywords

ADHESION; BIOACTIVITY; CELL ADHESION; CELL CULTURE; CELL MEMBRANES; CELL PROLIFERATION; CELLS; CYTOLOGY; ENZYME INHIBITION; GLYCOPROTEINS; TISSUE HOMEOSTASIS; TUMORS;

DISCOIDIN DOMAIN RECEPTORS; INTEGRINS; MIGRATION; PROTEOGLYCANS; SYNDECAN;

CELL SIGNALING;

CELL SURFACE RECEPTOR; CHEMOKINE; COLLAGEN; CYTOKINE; DISCOIDIN; FIBRONECTIN; GLYCOPROTEIN; GROWTH FACTOR; HERMES ANTIGEN; INTEGRIN; PROTEOGLYCAN; SYNDECAN; TRANSFORMING GROWTH FACTOR BETA;

BASEMENT MEMBRANE; BREAST CARCINOMA; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL MOTILITY; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GLIOMA; HUMAN; IMMUNOSURVEILLANCE; MACROMOLECULE; NEOPLASM; NON SMALL CELL LUNG CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; PROTEOGLYCANS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84957823774     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.10.013     Document Type: Review

References (211)

1. Bolós V., Gasent J.M., López-Tarruella S., Grande E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Oncol. Targets Ther. 2010, 24:83-97.
2. Zhao X.L., Guan J.L. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv. Drug Deliv. Rev. 2011, 63:610-615.
3. Paoli P., Giannoni E., Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim. Biophys. Acta 2013, 1833:3481-3498.
4. Ginsberg M.H. Integrin activation. BMB Rep. 2014, 47:655-659.
5. Yang J., Zhu L., Zhang H., Hirbawi J., Fukuda K., Dwivedi P., Liu J., Byzova T., Plow E.F., Wu J., Qin J. Conformational activation of talin by RIAM triggers integrin-mediated cell adhesion. Nat. Commun. 2014, 5:5880.
6. Case L.B., Baird M.A., Shtengel G., Campbell S.L., Hess H.F., Davidson M.W., Waterman C.M. Molecular mechanism of vinculin activation and nanoscale spatial organization in focal adhesions. Nat. Cell Biol. 2015, 880-892. (bakin).
7. Sun C.C., Qu X.J., Gao Z.H. Integrins: players in cancer progression and targets in cancer therapy. Anti-cancer Drugs 2014, 25:1107-1121.
8. Schlesinger M., Bendas G. Contribution of very later antigen-4 (VLA-4) integrin to cancer progression and metastasis. Cancer Metastasis Rev. 2015, 10.1007/s10555-014-9545-x.
9. Seguin L., Desgrosellier J.S., Weis S.M., Cheresh D.A. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015, 25:234-240.
10. Naci D., Vuori K., Aoudjit F. Alpha2beta1 integrin in cancer development and chemoresistance. Semin. Cancer Biol. 2015, (S1044-579X(15)00067-X). 10.1016/j.semcancer.2015.08.004.
11. Cantor D.I., Cheruku H.R., Nice E.C., Baker M.S. Integrin αvβ6 sets the stage for colorectal cancer metastasis. Cancer Metastasis Rev. 2015, 10.1007/s10555-015-9591-z.
12. Franco O.E., Shaw A.K., Strand D.W., Hayward S.W. Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 2010, 21:33-39.
13. Haviv I., Polyak K., Qiu W., Hu M., Campbell I. Origin of carcinoma associated fibroblasts. Cell Cycle 2009, 8:589-595.
14. Kalluri R., Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
15. Rybinski B., Franco-Barraza J., Cukierman E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol. Genomics 2014, 46:223-244.
16. Östman A., Augsten M. Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr. Opin. Genet. Dev. 2009, 19:67-73.
17. Pietras K., Östman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 2010, 316:1324-1331.
18. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
19. Samuel M.S., Lopez J.I., McGhee E.J., Croft D.R., Strachan D., Timpson P., Munro J., Schröder E., Zhou J., Brunton V.G., Barker N., Clevers H., Sansom O.J., Anderson K.I., Weaver V.M., Olson M.F. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011, 19:776-791.
20. Eke I., Cordes N. Focal adhesions signaling and therapy resitance in cancer. Semin. Cancer Biol. 2015, 31:65-75.
21. Rhim A.D., Oberstein P.E., Thomas D.H., Mirek E.T., Palermo C.F., Sastra S.A., Dekleva E.N., Saunders T., Becerra C.P., Tattersall I.W., Westphalen C.B., Kitajewski J., Fernandez-Barrena M.G., Fernandez-Zapico M.E., Iacobuzio-Donahue C., Olive K.P., Stanger B.Z. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014, 25:735-747.
22. Reed N.I., Jo H., Chen C., Tsujino K., Arnold T.D., DeGrado W.F., Sheppard D. The alphavbeta1 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl. Med. 2015, 7:288ra79.
23. Kramann R., Schneider R.K., DiRocco D.P., Machado F., Fleig S., Bondzie P.A., Henderson J.M., Ebert B.L., Humphreys B.D. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015, 16:51-66.
24. Ng C.P., Hinz B., Swartz M.A. Interstitial fluid flow induces myofibroblast differentiation and collagen alignement in vitro. J. Cell Sci. 2005, 118(Pt20):4731-4739.
25. Arora P.D., Natani N., McCulloch C.A. The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts. Am. J. Pathol. 1999, 154:871-882.
26. Honda E.K., Yoshida K., Munakata H. Transforming growth factor-beta upregulates the expression of intergrin and related proteinsin MRC-5 human myofibroblasts. Tohoku J. Exp. Med. 2010, 220:319-327.
27. Kohan M., Muro A.F., White E.S., Berkman N. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J. 2010, 24:4503-4512.
28. Bakin J.S., Nakayama K., Gilbert C.D. Visual responses in monkey areas V1 and V2 to three-dimensional surface configurations. J. Neurosci. 2000, 20:8188-8198.
29. Ramos D.M., Dang D., Sadler S. The role of the integrin alphav beta6 in regulating the epithelial to mesenchymal transition in oral cancer. Anticancer Res. 2009, 29:125-130.
30. Nakayama Y., Kon S., Kuritaki D., Morimoto J., Matsui Y., Uede T. Blockade of interaction of alpha9 integrin with its ligands hinders the formation of granulation in cutaneous wound healing. Lab. Investig. 2010, 90:881-894.
31. Danussi C., Petrucco A., Wassermann B., Pivetta E., Modica T.M., Del Bel Belluz L., Colombatti A., Spessotto P. EMILIN1-α4/α9 integrin interaction inhibits dermal fibroblasts and keratinocyte proliferation. J. Cell Biol. 2011, 195:131-145.
32. Asano Y., Ihn H., Yamane K., Jinnin M., Tamaki K. Increased expression of integrin alphavbeta5 induces the myoblastic differentiation of dermal fibroblasts. Am. J. Pathol. 2006, 168:499-510.
33. Payne S.J., Jones L. Influence of the tumor microenvironment on angiogenesis. Future Oncol. 2011, 7:395-408.
34. Arora P.D., Wang Y., Janmey P.A., Bresnick A., Yin H.L., McCulloch C.A. Gelsolin and non-muscle myosin IIA interact to mediate calcium-regulated collagen phagocytosis. J. Biol. Chem. 2011, 286:34184-34198.
35. Rodriguez A., Karen J., Gardner H., Gerdin B., Rubin K., Sundberg C. Integrin alpha1beta1 is involved in the differentiation into myofibroblasts in adult reactive tissues in vivo. J. Cell. Mol. Med. 2009, 13:3449-3462.
36. Wu J.E., Santoro S.A. Complex patterns of expression suggest extensive roles for the a2b1 integrin in murine development. Dev. Dyn. 1994, 199:292-314.
37. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., Gardner H.A. Elevated matrix metalloprotease and angiostatin levels in integrin a1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2202-2207.
38. Hemler M.E., Jacobson J.G., Strominger J.L. Biochemical characterization of VLA-1 and VLA-2. Cell surface heterodimers on activated T cells. J. Biol. Chem. 1985, 260:15246-15252.
39. Camper L., Holmvall K., Wängnerud C., Aszódi A., Lundgren-Akerlund E. Distribution of the collagen-binding integrin alpha10beta1 during mouse development. Cell Tissue Res. 2001, 306:107-116.
40. Wenke A.K., Kjellman C., Lundgren-Akerlund E., Uhlmann C., Haass N.K., Herlyn M., Bosserhoff A.K. Expression of integrin alpha10 is induced in malignant melanoma. Cell. Oncol. 2007, 29:373-386.
41. Schulz J.N., Zeltz C., Sørensen I.W., Barczyk M., Carracedo S., Hallinger R., Niehoff A., Eckes B., Gullberg D. Reduced granulation tissue and wound strength in the absence of alpha11beta1 integrin. J. Invest. Dermatol. 2015, 135:1435-1444.
42. Navab R., Strumpf D., C.To, Pasko E., Kim K.S., Park C.J., Hai J., Liu J., Jonkman J., Barczyk M., Bandarchi B., Wang Y.H., Venkat K., Ibrahimov E., Pham N.A., Ng C., Radulovich N., Zhu C.Q., Pintilie M., Wang D., Lu A., JurisicaI I., Walker G.C., Gullberg D., Tsao M.S. Integrin alpha11beta1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer. Oncogene 2015, 10.1038/onc.
43. Carracedo S., Lu N., Popova S.N., Jonsson R., Eckes B., Gullberg D. The fibroblast integrin alpha11beta1 is induced in a mechanosensitive manner involving activin A and regulates myofibroblast differentiation. J. Biol. Chem. 2010, 285:10434-10445.
44. Talior-Volodarsky I., Connelly K.A., Arora P.D., Gullberg D., McCulloch C.A. alpha11 integrin stimulates myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc. Res. 2012, 96:265-275.
45. Lu N., Karlsen T.V., Reed R.K., Kusche-Gullberg M., Gullberg D. Fibroblast alpha11beta1 integrin regulates tensional homeostasis in fibroblast/A549 carcinoma heterospheroids. PLoS One 2014, 9.
46. Talior-Volodarsky I., Arora P.D., Wang Y., Zeltz C., Connelly K.A., Gullberg D., McCulloch C.A. Glycated collagen induces alpha11 integrin expression through TGF-beta2 and Smad3. J. Cell. Physiol. 2015, 230:327-336.
47. Zhu C.Q., Popova S.N., Brown E.R., Barsyte-Lovejoy D., Navab R., Shih W., Li M., Lu M., Jurisica I., Penn L.Z., Gullberg D., Tsao M.S. Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11754-11759.
48. Westcott J.M., Prechtl A.M., Maine E.A., Dang T.T., Esparza M.A., Sun H., Zhou Y., Xie Y., Pearson G.W. An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. J. Clin. Invest. 2015, 125:1927-1943.
49. Liu S., Xu S.W., Blumbach K., Eastwood M., Denton C.P., Eckes B., Krieg T., Abraham D.J., Leask A. Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo. J. Cell Sci. 2010, 123:3674-3682.
50. Astrof S., Hynes R.O. Fibronectins in vascular morphogenesis. Angiogenesis 2009, 12:165-175.
51. Shinde A.V., Bystroff C., Wang C., Vogelezang M.G., Vincent P.A., Hynes P.O., Van De Water L. Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities. J. Biol. Chem. 2008, 283:2858-2870.
52. Manabe R., Ohe N., Maeda T., Fukuda T., Sekiguchi K. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J. Cell Biol. 1997, 139:295-307.
53. Serini G., Bochaton-Pialla M.L., Ropraz P., Geinoz A., Borsi L., Zardi L., Gabbiani G. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J. Cell Biol. 1998, 142:873-881.
54. Arslan F., Smeets M.B., Riem Vis P.W., Karper J.C., Quax P.H., Bongartz L.G., Peters J.H., Hoefer I.E., Doevendans P.A., Pasterkamp G., de Kleijn D.P. Lack of fibronectin-EDA promotes survival and prevents adverse remodeling and heart function deterioration after myocardial infarction. Circ. Res. 2011, 108:582-592.
55. Kelsh R.M., McKeown-Longo P.J., Clark R.A. EDA fibronectin in keloids create a vicious cycle of fibrotic tumor formation. J. Invest. Dermatol. 2015, 135:1714-1718.
56. Henderson N.C., Arnold T.D., Katamura Y., Giacomini M.M., Rodriguez J.D., McCarty J.H., Pellicoro A., Raschperger E., Betsholtz C., Ruminski P.G., Griggs D.W., Prinsen M.J., Maher J.J., Iredale J.P., Lacy-Hulbert A., Adams R.H., Sheppard D. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 2013, 19:1617-1624.
57. Wipff P.J., Rifkin D.B., Meister J.J., Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 2007, 179:1311-1323.
58. Kitamura H., Cambier S., Somanath S., Barker T., Minagawa S., Markovics J., Goodsell A., Publicover J., Reichardt L., Jablons D., Wolters P., Hill A., Marks J.D., Lou J., Pittet J.F., Gauldie J., Baron J.L., Nishimura S.L. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J. Clin. Invest. 2011, 121:2863-2875.
59. Klingberg F., Chow M.L., Koehler A., Boo S., Buscemi L., Quinn T.M., Costell M., Alman B.A., Genot E., Hinz B. Prestress in the extracellular matrix sensitizes latent TGF-beta1 for activation. J. Cell Biol. 2014, 207:283-297.
60. Honda S., Shirotani-Ikejima H., Tadokoro S., Maeda Y., Kinoshita T., Tomiyama Y., Miyata T. Integrin-linked kinase associated with integrin activation. Blood 2009, 113:5304-5313.
61. Ozdemir B.C., Pentcheva-Hoang T., Carstens J.L., Zheng X., Wu C.C., Simpson T.R., Laklai H., Sugimoto H., Kahlert C., Novitskiy S.V., De Jesus-Acosta A., Sharma P., Heidari P., Mahmood U., Chin L., Moses H.L., Weaver V.M., Maitra A., Allison J.P., LeBleu V.S., Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25:719-734.
62. Hinz B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 2007, 127:526-537.
63. Liu S., Taghavi R., Leask A. Connective tissue growth factor is induced in bleomycin-induced skin scleroderma. J. Cell. Commun. Signal. 2010, 4:25-30.
64. Driskell R.R., Lichtenberger B.M., Hoste E., Kretzschmar K., Simons B.D., Charalambous M., Ferron S.R., Herault Y., Pavlovic G., Ferguson-Smith A.C., Watt F.M. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 2013, 504:277-281.
65. Rinkevich Y., Walmsley G.G., Hu M.S., Maan Z.N., Newman A.M., Drukker M., Januszyk M., Krampitz G.W., Gurtner G.C., Lorenz H.P., Weissman I.L., Longaker M.T., Skin fibrosis Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science 2015, 348:aaa2151.
66. Bremnes R.M., Al-Shibli K., Donnem T., Sirera R., Al-Saad S., Andersen S., Stenvold H., Camps C., Busund L.T. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:209-217.
67. Liu S., Kapoor M., Denton C.P., Abraham D.J., Leask A. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum. 2009, 60:2817-2821.
68. Shimoda M., Mellody K.T., Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin. Cell Dev. Biol. 2010, 21:19-25.
69. Pietras K., Pahler J., Bergers G., Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008, 5.
70. Hooper S., Gaggioli C., Sahai E. A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion. Br. J. Cancer 2010, 102:392-402.
71. Erler J.T., Bennewith K.L., Nicolau M., Dornhöfer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
72. Baker A.M., Bird D., Lang G., Cox T.R., Erler J.T. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 2013, 32:1863-1868.
73. Miller B.W., Morton J.P., Pinese M., Saturno G., Jamieson N.B., McGhee E., Timpson P., Leach J., McGarry L., Shanks E., Bailey P., Chang D., Oien K., Karim S., Au A., Steele C., Carter C.R., McKay C., Anderson K., Evans T.R., Marais R., Springer C., Biankin A., Erler J.T., Sansom O.J. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Mol. Med. 2015, 7:1063-1076.
74. Hinz B. The extracellular matrix and transforming growth factor-beta1: Tale of a strained relationship. Matrix Biol. 2015, 10.1016/j.
75. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9:1392-1400.
76. Medjkane S., Perez-Sanchez C., Gaggioli C., Sahai E., Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat. Cell Biol. 2009, 11:257-268.
77. Sanz-Moreno V., Gaggioli C., Yeo M., Albrengues J., Wallberg F., Viros A., Hooper S., Mitter R., Féral C.C., Cook M., Larkin J., Marais R., Meneguzzi G., Sahai E., Marshall C.J. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma cancer. Cell 2011, 20:229-245.
78. Calvo F., Ege N., Grande-Garcia A., Hooper S., Jenkins R.P., Chaudhry S.I., Harrington K., Williamson P., Moeendarbary E., Charras G., Sahai E. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 2013, 15:637-646.
79. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fukumura D., Jain R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21677-21682.
80. Fu H.L., Valiathan R.R., Arkwright R., Sohail A., Mihai C., Kumarasiri M., Mahasenan K.V., Mobashery S., Huang P., Agarwal G., Fridman R. Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J. Biol. Chem. 2013, 288:7430-7437.
81. Leitinger B. Discoidin domain receptor functions in physiological and pathological conditions. Int. Rev. Cell Mol. Biol. 2014, 310:39-87.
82. Carafoli F., Mayer M.C., Shiraishi K., Pecheva M.A., Chan L.Y., Nan R., Leitinger B., Hohenester E. Structure of the discoidin domain receptor 1 extracellular region bound to an inhibitory Fab fragment reveals features important for signaling. Structure 2012, 20:688-697.
83. Valiathan R.R., Marco M., Leitinger B., Kleer C.G., Fridman R. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metastasis Rev. 2012, 31:295-321.
84. Borza C.M., Pozzi A. Discoidin domain receptors in disease. Matrix Biol. 2014, 34:185-192.
85. Vogel W., Gish G.D., Alves F., Pawson T. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol. Cell 1997, 1:13-23.
86. Shrivastava A., Radziejewski C., Campbell E., Kovac L., McGlynn M., Ryan T.E., Davis S., Goldfarb M.P., Glass D.J., Lemke G., Yancopoulos G.D. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol. Cell 1997, 1:25-34.
87. Leitinger B. Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2. Identification of collagen binding sites in DDR2. J. Biol. Chem. 2003, 278:16761-16769.
88. Konitsiotis A.D., Raynal N., Bihan D., Hohenester E., Farndale R.W., Leitinger B. Characterization of high affinity binding motifs for the discoidin domain receptor DDR2 in collagen. J. Biol. Chem. 2008, 283:6861-6868.
89. Xu H., Raynal N., Stathopoulos S., Myllyharju J., Farndale R.W., Leitinger B. Collagen binding specificity of the discoidin domain receptors: binding sites on collagens II and III and molecular determinants for collagen IV recognition by DDR1. Matrix Biol. 2011, 30:16-26.
90. Ichikawa O., Osawa M., Nishida N., Goshima N., Nomura N., Shimada I. Structural basis of the collagen-binding mode of discoidin domain receptor 2. EMBO J. 2007, 26:4168-4176.
91. Carafoli F., Bihan D., Stathopoulos S., Konitsiotis A.D., Kvansakul M., Farndale R.W., Leitinger B., Hohenester E. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Structure 2009, 17:1573-1581.
92. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
93. Noordeen N.A., Carafoli F., Hohenester E., Horton M.A., Leitinger B. A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1. J. Biol. Chem. 2006, 281:22744-22751.
94. Mihai C., Chotani M., Elton T.S., Agarwal G. Mapping of DDR1 distribution and oligomerization on the cell surface by FRET microscopy. J. Mol. Biol. 2009, 385:432-445.
95. Xu H., Abe T., Liu J.K., Zalivina I., Hohenester E., Leitinger B. Normal activation of discoidin domain receptor 1 mutants with disulfide cross-links, insertions, or deletions in the extracellular juxtamembrane region: mechanistic implications. J. Biol. Chem. 2014, 289:13565-13574.
96. Ikeda K., Wang L.H., Torres R., Zhao H., Olaso E., Eng F.J., Labrador P., Klein R., Lovett D., Yancopoulos G.D., Friedman S.L., Lin H.C. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J. Biol. Chem. 2002, 277:19206-19212.
97. Koo D.H., McFadden C., Huang Y., Abdulhussein R., Friese-Hamim M., Vogel W.F. Pinpointing phosphotyrosine-dependent interactions downstream of the collagen receptor DDR1. FEBS Lett. 2006, 580:15-22.
98. Abbonante V., Gruppi C., Rubel D., Gross O., Moratti R., Balduini A. Discoidin domain receptor 1 protein is a novel modulator of megakaryocyte-collagen interactions. J. Biol. Chem. 2013, 288:16738-16746.
99. Wang C.Z., Su H.W., Hsu Y.C., Shen M.R., Tang M.J. A discoidin domain receptor 1/SHP-2 signaling complex inhibits 2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration. Mol. Biol. Cell 2006, 17:2839-2852.
100. Faraci-Orf E., McFadden C., Vogel W.F. DDR1 signaling is essential to sustain Stat5 function during lactogenesis. J. Cell. Biochem. 2006, 97:109-121.
101. Iwai L.K., Payne L.S., Luczynski M.T., Chang F., Xu H., Clinton R.W., Paul A., Esposito E.A., Gridley S., Leitinger B., Naegle K.M., Huang P.H. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochem. J. 2013, 454:501-513.
102. Lu K.K., Trcka D., Bendeck M.P. Collagen stimulates discoidin domain receptor 1-mediated migration of smooth muscle cells through Src. Cardiovasc. Pathol. 2011, 20:71-76.
103. Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W., Daly R.J., Ormandy C.J. KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling. Biochim. Biophys. Acta 2008, 1783:383-393.
104. Curat C.A., Vogel W.F. Discoidin domain receptor 1 controls growth and adhesion of mesangial cells. J. Am. Soc. Nephrol. 2002, 13:2648-2656.
105. Ghosh S., Ashcraft K., Jahid M.J., April C., Ghajar C.M., Ruan J., Wang H., Foster M., Hughes D.C., Ramirez A.G., Huang T., Fan J.B., Hu Y., Li R. Regulation of adipose oestrogen output by mechanical stress. Nat. Commun. 2013, 4:1821.
106. Xu L., Peng H., Glasson S., Lee P.L., Hu K., Ijiri K., Olsen B.R., Goldring M.B., Li Y. Increased expression of the collagen receptor discoidin domain receptor 2 in articular cartilage as a key event in the pathogenesis of osteoarthritis. Arthritis Rheum. 2007, 56:2663-2673.
107. Poudel B., Ki H.H., Lee Y.M., Kim D.K. Induction of IL-12 production by the activation of discoidin domain receptor 2 via NF-kappaB and JNK pathway. Biochem. Biophys. Res. Commun. 2013, 434:584-588.
108. Lin K.L., Chou C.H., Hsieh S.C., Hwa S.Y., Lee M.T., Wang F.F. Transcriptional upregulation of DDR2 by ATF4 facilitates osteoblastic differentiation through p38 MAPK-mediated Runx2 activation. J. Bone Miner. Res. 2010, 25:2489-2503.
109. Zhang Y., Su J., Yu J., Bu X., Ren T., Liu X., Yao L. An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation. J. Bone Miner. Res. 2011, 26:604-617.
110. Hidalgo-Carcedo C., Hooper S., Chaudhry S.I., Williamson P., Harrington K., Leitinger B., Sahai E. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat. Cell Biol. 2011, 13:49-58.
111. Valencia K., Ormazabal C., Zandueta C., Luis-Ravelo D., Anton I., Pajares M.J., Agorreta J., Montuenga L.M., Martinez-Canarias S., Leitinger B., Lecanda F. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin. Cancer Res. 2012, 18:969-980.
112. Cader F.Z., Vockerodt M., Bose S., Nagy E., Brundler M.A., Kearns P., Murray P.G. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood 2013, 122:4237-4245.
113. Kim H.G., Hwang S.Y., Aaronson S.A., Mandinova A., Lee S.W. DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation. J. Biol. Chem. 2011, 286:17672-17681.
114. Jian Z.X., Sun J., Chen W., Jin H.S., Zheng J.H., Wu Y.L. Involvement of discoidin domain 1 receptor in recurrence of hepatocellular carcinoma by genome-wide analysis. Med. Oncol. 2012, 29:3077-3082.
115. Zhang K., Corsa C.A., Ponik S.M., Prior J.L., Piwnica-Worms D., Eliceiri K.W., Keely P.J., Longmore G.D. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat. Cell Biol. 2013, 15:677-687.
116. Hammerman P.S., Sos M.L., Ramos A.H., Xu C., Dutt A., Zhou W., Brace L.E., Woods B.A., Lin W., Zhang J., Deng X., Lim S.M., Heynck S., Peifer M., Simard J.R., Lawrence M.S., Onofrio R.C., Salvesen H.B., Seidel D., Zander T., Heuckmann J.M., Soltermann A., Moch H., Koker M., Leenders F., Gabler F., Querings S., Ansen S., Brambilla E., Brambilla C., Lorimier P., Brustugun O.T., Helland A., Petersen I., Clement J.H., Groen H., Timens W., Sietsma H., Stoelben E., Wolf J., Beer D.G., Tsao M.S., Hanna M., Hatton C., Eck M.J., Janne P.A., Johnson B.E., Winckler W., Greulich H., Bass A.J., Cho J., Rauh D., Gray N.S., Wong K.K., Haura E.B., Thomas R.K., Meyerson M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011, 1:78-89.
117. Payne L.S., Huang P.H. The pathobiology of collagens in glioma. Mol. Cancer Res. 2013, 11:1129-1140.
118. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague J., Butler A., Edkins S., Stevens C., Parker A., O'Meara S., Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.T., Yuen S.T., Lakhani S.R., Easton D.F., Weber B.L., Goldstraw P., Nicholson A.G., Wooster R., Stratton M.R., Futreal P.A. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005, 65:7591-7595.
119. Ford C.E., Lau S.K., Zhu C.Q., Andersson T., Tsao M.S., Vogel W.F. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Br. J. Cancer 2007, 96:808-814.
120. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., Fulton L., Fulton R.S., Zhang Q., Wendl M.C., Lawrence M.S., Larson D.E., Chen K., Dooling D.J., Sabo A., Hawes A.C., Shen H., Jhangiani S.N., Lewis L.R., Hall O., Zhu Y., Mathew T., Ren Y., Yao J., Scherer S.E., Clerc K., Metcalf G.A., Ng B., Milosavljevic A., Gonzalez-Garay M.L., Osborne J.R., Meyer R., Shi X., Tang Y., Koboldt D.C., Lin L., Abbott R., Miner T.L., Pohl C., Fewell G., Haipek C., Schmidt H., Dunford-Shore B.H., Kraja A., Crosby S.D., Sawyer C.S., Vickery T., Sander S., Robinson J., Winckler W., Baldwin J., Chirieac L.R., Dutt A., Fennell T., Hanna M., Johnson B.E., Onofrio R.C., Thomas R.K., Tonon G., Weir B.A., Zhao X., Ziaugra L., Zody M.C., Giordano T., Orringer M.B., Roth J.A., Spitz M.R., Wistuba I.I., Ozenberger B., Good P.J., Chang A.C., Beer D.G., Watson M.A., Ladanyi M., Broderick S., Yoshizawa A., Travis W.D., Pao W., Province M.A., Weinstock G.M., Varmus H.E., Gabriel S.B., Lander E.S., Gibbs R.A., Meyerson M., Wilson R.K. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
121. Pitini V., Arrigo C., Di Mirto C., Mondello P., Altavilla G. Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer 2013, 82:171-172.
122. An S.J., Chen Z.H., Su J., Zhang X.C., Zhong W.Z., Yang J.J., Zhou Q., Yang X.N., Huang L., Guan J.L., Nie Q., Yan H.H., Mok T.S., Wu Y.L. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS One 2012, 7.
123. Miao L., Wang Y., Zhu S., Shi M., Li Y., Ding J., Yang J., Ye Q., Cai H., Zhang D., Liu H., Song Y. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. BMC Cancer 2014, 14:369.
124. Konig K., Peifer M., Fassunke J., Ihle M.A., Kunstlinger H., Heydt C., Stamm K., Ueckeroth F., Vollbrecht C., Bos M., Gardizi M., Scheffler M., Nogova L., Leenders F., Albus K., Meder L., Becker K., Florin A., Rommerscheidt-Fuss U., Altmuller J., Kloth M., Nurnberg P., Henkel T., Bikar S.E., Sos M.L., Geese W.J., Strauss L., Ko Y.D., Gerigk U., Odenthal M., Zander T., Wolf J., Merkelbach-Bruse S., Buettner R., Heukamp L.C. Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients. J. Thorac. Oncol. 2015, 10:1049-1057.
125. Bai Y., Kim J.Y., Watters J.M., Fang B., Kinose F., Song L., Koomen J.M., Teer J.K., Fisher K., Chen Y.A., Rix U., Haura E.B. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res. 2014, 74:7217-7228.
126. Murray C.W., Berdini V., Buck I.M., Carr M.E., Cleasby A., Coyle J.E., Curry J.E., Day J.E., Day P.J., Hearn K., Iqbal A., Lee L.Y., Martins V., Mortenson P.N., Munck J.M., Page L.W., Patel S., Roomans S., Smith K., Tamanini E., Saxty G. Fragment-based discovery of potent and selective DDR1/2 inhibitors. ACS Med. Chem. Lett. 2015, 6:798-803.
127. Yang S.H., Baek H.A., Lee H.J., Park H.S., Jang K.Y., Kang M.J., Lee D.G., Lee Y.C., Moon W.S., Chung M.J. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol. Rep. 2010, 24:311-319.
128. Miao L., Zhu S., Wang Y., Li Y., Ding J., Dai J., Cai H., Zhang D., Song Y. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung cancer and promotes cell invasion via epithelial-to-mesenchymal transition. Med. Oncol. 2013, 30:626.
129. Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.L., Polakiewicz R.D., Rush J., Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
130. Xiao Q., Jiang Y., Liu Q., Yue J., Liu C., Zhao X., Qiao Y., Ji H., Chen J., Ge G. Minor type IV collagen alpha5 chain promotes cancer progression through discoidin domain receptor-1. PLoS Genet. 2015, 11.
131. Vogel W.F., Aszodi A., Alves F., Pawson T. Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. Mol. Cell. Biol. 2001, 21:2906-2917.
132. Koh M., Woo Y., Valiathan R.R., Jung H.Y., Park S.Y., Kim Y.N., Kim H.R., Fridman R., Moon A. Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition. Int. J. Cancer 2015, 136:E508-E520.
133. Barker K.T., Martindale J.E., Mitchell P.J., Kamalati T., Page M.J., Phippard D.J., Dale T.C., Gusterson B.A., Crompton M.R. Expression patterns of the novel receptor-like tyrosine kinase, DDR, in human breast tumours. Oncogene 1995, 10:569-575.
134. Neuhaus B., Buhren S., Bock B., Alves F., Vogel W.F., Kiefer F. Migration inhibition of mammary epithelial cells by Syk is blocked in the presence of DDR1 receptors. Cell. Mol. Life Sci. 2011, 68:3757-3770.
135. Turashvili G., Bouchal J., Baumforth K., Wei W., Dziechciarkova M., Ehrmann J., Klein J., Fridman E., Skarda J., Srovnal J., Hajduch M., Murray P., Kolar Z. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55.
136. Ren T., Zhang J., Liu X., Yao L. Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients. Med. Oncol. 2013, 30:397.
137. Toy K.A., Valiathan R.R., Nunez F., Kidwell K.M., Gonzalez M.E., Fridman R., Kleer C.G. Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer. Breast Cancer Res. Treat. 2015, 150:9-18.
138. Badiola I., Villace P., Basaldua I., Olaso E. Downregulation of discoidin domain receptor 2 in A375 human melanoma cells reduces its experimental liver metastasis ability. Oncol. Rep. 2011, 26:971-978.
139. Zhang S., Bu X., Zhao H., Yu J., Wang Y., Li D., Zhu C., Zhu T., Ren T., Liu X., Yao L., Su J. A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis. J. Pathol. 2014, 232:436-448.
140. Canning P., Tan L., Chu K., Lee S.W., Gray N.S., Bullock A.N. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J. Mol. Biol. 2014, 426:2457-2470.
141. Kothiwale S., Borza C.M., Lowe E.W., Pozzi A., Meiler J. Discoidin domain receptor 1 (DDR1) kinase as target for structure-based drug discovery. Drug Discov. Today 2015, 20:255-261.
142. Li Y., Lu X., Ren X., Ding K. Small molecule discoidin domain receptor kinase inhibitors and potential medical applications. J. Med. Chem. 2015, 58:3287-3301.
143. Day E., Waters B., Spiegel K., Alnadaf T., Manley P.W., Buchdunger E., Walker C., Jarai G. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur. J. Pharmacol. 2008, 599:44-53.
144. Rix U., Hantschel O., Durnberger G., Remsing Rix L.L., Planyavsky M., Fernbach N.V., Kaupe I., Bennett K.L., Valent P., Colinge J., Kocher T., Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007, 110:4055-4063.
145. Gao M., Duan L., Luo J., Zhang L., Lu X., Zhang Y., Zhang Z., Tu Z., Xu Y., Ren X., Ding K. Discovery and optimization of 3-(2-(pyrazolo[(1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J. Med. Chem. 2013, 56:3281-3295.
146. Kim H.G., Tan L., Weisberg E.L., Liu F., Canning P., Choi H.G., Ezell S.A., Wu H., Zhao Z., Wang J., Mandinova A., Griffin J.D., Bullock A.N., Liu Q., Lee S.W., Gray N.S. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem. Biol. 2013, 8:2145-2150.
147. Richters A., Nguyen H.D., Phan T., Simard J.R., Grutter C., Engel J., Rauh D. Identification of type II and III DDR2 inhibitors. J. Med. Chem. 2014, 57:4252-4262.
148. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., Usary J., Kuan P.F., Smalley D.M., Major B., He X., Hoadley K.A., Zhou B., Sharpless N.E., Perou C.M., Kim W.Y., Gomez S.M., Chen X., Jin J., Frye S.V., Earp H.S., Graves L.M., Johnson G.L. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
149. Stuhlmiller T.J., Miller S.M., Zawistowski J.S., Nakamura K., Beltran A.S., Duncan J.S., Angus S.P., Collins K.A., Granger D.A., Reuther R.A., Graves L.M., Gomez S.M., Kuan P.F., Parker J.S., Chen X., Sciaky N., Carey L.A., Earp H.S., Jin J., Johnson G.L. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 2015, 11:390-404.
150. Xu D., Esko J.D. Demystifying heparan sulfate-protein interactions. Annu. Rev. Biochem. 2014, 83:129-157.
151. Bart G., Vico N.O., Hassinen A., Pujol F.M., Deen A.J., Ruusala A., Tammi R.H., Squire A., Heldin P., Kellokumpu S., Tammi M.I. Fluorescence resonance energy transfer (FRET) and proximity ligation assays reveal functionally relevant homo- and heterodimeric complexes among hyaluronan synthases HAS1, HAS2, and HAS3. J. Biol. Chem. 2015, 290:11479-11490.
152. Milner C.M., Tongsoongnoen W., Rugg M.S., Day A.J. The molecular basis of inter-alpha-inhibitor heavy chain transfer on to hyaluronan. Biochem. Soc. Trans. 2007, 35:672-676.
153. Nikitovic D., Tzardi M., Berdiaki A., Tsatsakis A., Tzanakakis G.N. Cancer microenvironment and inflammation: role of hyaluronan. Front. Immunol. 2015, 6:169.
154. Kreuger J., Kjellén L. Heparan sulfate biosynthesis: regulation and variability. J. Histochem. Cytochem. 2012, 60:898-907.
155. Malmström A., Bartolini B., Thelin M.A., Pacheco B., Maccarana M. Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function. J. Histochem. Cytochem. 2012, 60:916-925.
156. S. Mizumoto, S. Yamada, K Sugahara, Molecular interactions between chondroitin-dermatan sulfate and growth factors/receptors/matrix proteins.
157. Filmus J., Capurro M., Rast J. Glypicans. Genome Biol. 2008, 9:224.
158. Filmus J., Capurro M. The glypican family. Extracellular Matrix: Pathobiology and Signaling 2012, 209-220. De Gruyter, Berlin/Boston. N.K. Karamanos (Ed.).
159. Gallagher J. Fell-Muir lecture: heparan sulphate and the art of cell regulation: a polymer chain conducts the protein orchestra. Int. J. Exp. Pathol. 2015, 96:203-231.
160. Xian X., Gopal S., Couchman J.R. Syndecans as receptors and organizers of the extracellular matrix. Cell Tissue Res. 2010, 229:31-46.
161. Lowy C.M., Oskarsson T. Tenascin C in metastasis: a view from the invasive front. Cell. Adh. Migr. 2015, 9:112-124.
162. Gurbuz I., Chiquet-Ehrismann R. CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): focus on its role in cancer. Int. J. Biochem. Cell Biol. 2015, 62:142-146.
163. Bax D.V., Mahalingam Y., Cain S., Mellody K., Freeman L., Younger K., Shuttleworth C.A., Humphries M.J., Couchman J.R., Kielty C.M. Cell adhesion to fibrillin-1: identification of an Arg-Gly-Asp-dependent synergy region and a heparin-binding site that regulates focal adhesion formation. J. Cell Sci. 2007, 120(Pt 8):1383-1392.
164. Morgan M.R., Humphries M.J., Bass M.D. Synergistic control of cell adhesion by integrins and syndecans. Nat. Rev. Mol. Cell Biol. 2007, 8:957-969.
165. Leahy D.J., Aukhil I., Erickson H.P. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop andsynergy region. Cell 1996, 84:155-164.
166. Sharma A., Askari J.A., Humphries M.J., Jones E.Y., Stuart D.I. Crystal structure of a heparin- and integrin-binding segment of human fibronection. EMBO J. 1999, 18:1468-1497.
167. Couchman J.R. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 2010, 26:89-114.
168. Couchman J.R., Gopal S., Lim H.C., Nørgaard S., Multhaupt H.A. Syndecans: from peripheral coreceptors to mainstream regulators of cell behavior. Int. J. Exp. Pathol. 2015, 96:1-10.
169. Choi S., Kim J.Y., Park J.H., Lee S.T., Han I.O., Oh E.S. The matrix metalloproteinase-7 regulates the extracelluar shedding of syndecan-2 from colon cancer cells. Biochem. Biophys. Res. Commun. 2012, 417:1260-1264.
170. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparin sulfate on syndecan-1. J. Biol. Chem. 2004, 279:10042-10051.
171. Munesue S., Yoshitomi Y., Kusano Y., Koyama Y., Nishiyama A., Nakanishi H., Miyazaki K., Ishimaru T., Miyaura S., Okayama M., Oguri K. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J. Biol. Chem. 2007, 282:28164-28174.
172. Thodeti C.K., Albrechtsen R., Grauslund M., Asmar M., Larsson C., Takada Y., Mercurio A.M., Couchman J.R., Wewer U.M. ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase Calpha and RhoA. J. Biol. Chem. 2003, 278:9576-9584.
173. Sanderson R.D., Couchman J.R. Targeting syndecan shedding in cancer. Extracellular Matrix: Pathobiology and Signaling 2012, 802-812. De Gruyter, Berlin/Boston. N.K. Karamanos (Ed.).
174. Cattaruzza S., Perris R. Proteoglycan control of cell movement during wound healing and cancer spreading. Matrix Biol. 2005, 24:400-417.
175. Price M.A., Colvin Wanshura L.E., Yang J., Carlson J., Xiang B., Li G., Ferrone S., Dudek A.Z., Turley E.A., McCarthy J.B. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011, 24:1148-1157.
176. Granés F., Berndt C., Roy C., Mangeat P., Reina M., Vilaró S. Identification of a novel Ezrin-binding site in syndecan-2 cytoplasmic domain. FEBS Lett. 2003, 547:212-216.
177. Mori T., Kitano K., Terawaki S., Maesaki R., Fukami Y., Hakoshima T. Structural basis for CD44 recognition by ERM proteins. J. Biol. Chem. 2008, 283:29602-29612.
178. Okina E., Grossi A., Gopal S., Multhaupt H.A., Couchman J.R. Alpha-actinin interactions with syndecan-4 are integral to fibroblast-matrix adhesion and regulate cytoskeletal architecture. Int. J. Biochem. Cell Biol. 2012, 44:2161-2174.
179. Fletcher D.A., Mullins R.D. Cell mechanics and the cytoskeleton. Nature 2010, 463:485-492.
180. Chen K., Williams K.J. Molecular mediators for raft-dependent endocytosis of syndecan-1, a highly conserved, multifunctional receptor. J. Biol. Chem. 2013, 288:13988-13999.
181. Gonzales J.C., Gordts P.L., Foley E.M., Esko J.D. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J. Clin. Invest. 2013, 123:2742-2751.
182. Boukerche H., Su Z.Z., Prévot C., Sarkar D., Fisher P.B. mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15914-15919.
183. Wawrzyniak A.M., Vermeiren E., Zimmermann P., Ivarsson Y. Extensions of PDS-95/disc large/ZO-1 (PDZ) domains influence lipid binding and membrane targeting of syntenin-1. FEBS Lett. 2012, 586:1445-1451.
184. Baietti M.F., Zhang Z., Mortier E., Melchior A., Degeest G., Geeraerts A., Ivarsson Y., Depoortere F., Coomans C., Vermeiren E., Zimmermann P., David G. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 2012, 14:677-685.
185. Melo S.A., Luecke L.B., Kahlert C., Fernandez A.F., Gammon S.T., Kaye J., LeBleu V.S., Mittendorf E.A., Weitz J., Rahbari N., Reissfelder C., Pilarsky C., Fraga M.F., Piwnica-Worms D., Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015, 523:177-182.
186. Orian-Rousseau V. CD44 Acts as a signaling platform controlling tumor progression and Metastasis. Front. Immunol. 2015, 6:154.
187. Aspberg A. The different roles of aggrecan interaction domains. J. Histochem. Cytochem. 2012, 60:987-996.
188. Günthert U., Hofmann M., Rudy W., Reber S., Zöller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65:13-24.
189. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur. J. Cancer 2010, 46:1271-1277.
190. Bourguignon L.Y., Bikle D. Selective hyaluronan-CD44 signaling promotes miRNA-21 expression and interacts with vitamin D function during cutaneous squamous cell carcinomas progression following UV irradiation. Front. Immunol. 2015, 6:224.
191. Misra S., Hascall V.C., Markwald R.R., Ghatak S. Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front. Immunol. 2015, 6:201.
192. Greenfield B., Wang W.C., Marquardt H., Piepkorn M., Wolff E.A., Aruffo A., Bennett K.L. Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44. J. Biol. Chem. 1999, 274:2511-2517.
193. Ajani J.A., Song S., Hochster H.S., Steinberg I.B. Cancer stem cells: the promise and the potential. Semin. Oncol. 2015, 42(Suppl. 1):S3-S17.
194. Vigetti D., Karousou E., Viola M., Deleonibus S., De Luca G., Passi A. Hyaluronan: biosynthesis and signaling. Biochim. Biophys. Acta 2014, 1840:2452-2459.
195. Couchman J.R., Vogt S., Lim S.T., Lim Y., Oh E.S., Prestwich G.D., Theibert A., Lee W., Woods A. Regulation of inositol phospholipid binding and signaling through syndecan-4. J. Biol. Chem. 2002, 277:49296-49303.
196. Oh E.S., Woods A., Lim S.T., Theibert A.W., Couchman J.R. Syndecan-4 proteoglycan cytoplasmic domain and phosphatidylinositol 4,5-bisphosphate coordinately regulate protein kinase C activity. J. Biol. Chem. 1998, 273:10624-10629.
197. Dovas A., Couchman J.R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem. J. 2005, 390:1-9.
198. Dovas A., Choi Y., Yoneda A., Multhaupt H.A., Kwon S.H., Kang D., Oh E.S., Couchman J.R. Serine 34 phosphorylation of rho guanine dissociation inhibitor (RhoGDIalpha) links signaling from conventional protein kinase C to RhoGTPase in cell adhesion. J. Biol. Chem. 2010, 285:23296-23308.
199. Yoneda A., Multhaupt H.A., Couchman J.R. The Rho kinases I and II regulate different aspects of myosin II activity. J. Cell Biol. 2005, 170:443-453.
200. Bass M.D., Morgan M.R., Roach K.A., Settleman J., Goryachev A.B., Humphries M.J. p190RhoGAP is the convergence point of adhesion signals from alpha 5 beta 1 integrin and syndecan-4. J. Cell Biol. 2008, 181:1013-1026.
201. Gopal S., Søgaard P., Multhaupt H.A.B., Pataki C., Okina E., Xian X., Pedersen M.E., Stevens T., Griesbeck O., Park P.W., Pocock R., Couchman J.R. Transmembrane proteoglycans control stretch-activated channels to set cytosolic calcium levels. J. Cell Biol. 2015, 210:1199-1211.
202. Trebak M.N., Hempel N., Wedel B.J., Smyth J.T., Bird G.S., Putney J.W. Negative regulation of the TRPC3 channels by protein kinase C-mediated phosphorylation of serine 712. Mol. Pharmacol. 2005, 67:558-563.
203. Goel M., Sinkins W., Keightley A., Kinter M., Schilling W.P. Proteomic analysis of TRPC5- and TRPC6-binding partners reveals interaction with the plasmalemmal Na+/K + -ATPase. Pflugers Arch. 2005, 451:87-98.
204. Yoneda A., Lendorf M.E., Couchman J.R., Multhaupt H.A. Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans. J. Histochem. Cytochem. 2012, 60:9-21.
205. Ramani V.C., Purushothaman A., Stewart M.D., Thompson C.A., Vlodavsky I., Au J.L., Sanderson R.D. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J. 2013, 280:2294-2306.
206. Lendorf M.E., Manon-Jensen T., Kronqvist P., Multhaupt H.A., Couchman J.R. Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J. Histochem. Cytochem. 2011, 59:615-629.
207. Alexander C.M., Reichsman F., Hinkes M.T., Lincecum J., Becker K.A., Cumberledge S., Bernfield M. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat. Genet. 2000, 25:329-332.
208. Farnedi A., Rossi S., Bertani N., Gulli M., Silini E.M., Mucignat M.T., Poli T., Sesenna E., Lanfranco D., Montebugnoli L., Leonardi E., Marchetti C., Cocchi R., Ambrosini-Spaltro A., Foschini M.P., Perris R. Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors. BMC Cancer 2015, 15:352.
209. Beauvais D.M., Ell B.J., McWhorter A.R., Rapraeger A.C. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J. Exp. Med. 2009, 206:691-705.
210. Rapraeger A.C. Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis. FEBS J. 2013, 280:2207-2215.
211. Whiteford J.R., Behrends V., Kirby H., Kusche-Gullberg M., Muramatsu T., Couchman J.R. Syndecans promote integrin-mediated adhesion of mesenchymal cells in two distinct pathways. Exp. Cell Res. 2007, 313:3902-3913.